These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1333 related articles for article (PubMed ID: 30356138)

  • 1. State-of-the-art strategies for targeting the DNA damage response in cancer.
    Pilié PG; Tang C; Mills GB; Yap TA
    Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of DNA Damage Response in Cancer.
    Choi W; Lee ES
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    Yap TA; Plummer R; Azad NS; Helleday T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
    Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    Brown JS; O'Carrigan B; Jackson SP; Yap TA
    Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
    Ngoi NYL; Westin SN; Yap TA
    Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing cancer therapy: new frontiers in targeting DNA damage response.
    Qian J; Liao G; Chen M; Peng RW; Yan X; Du J; Huang R; Pan M; Lin Y; Gong X; Xu G; Zheng B; Chen C; Yang Z
    Front Pharmacol; 2024; 15():1474337. PubMed ID: 39372203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA damage response inhibitors: An avenue for TNBC treatment.
    Jin J; Tao Z; Cao J; Li T; Hu X
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms.
    Garzón-Hernández C; Ramírez-Merino N; Soberon MCM
    Arch Med Res; 2022 Dec; 53(8):807-817. PubMed ID: 36460545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the DNA Damage Response in Cancer.
    O'Connor MJ
    Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G; Alholm Z; Coleman RL; Monk BJ
    Cancer J; 2021 Nov-Dec 01; 27(6):501-505. PubMed ID: 34904813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Directing the use of DDR kinase inhibitors in cancer treatment.
    Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
    Genta S; Martorana F; Stathis A; Colombo I
    Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.